Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front

Executive Summary

Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.

Advertisement

Related Content

MacroGenics Regains DART Asset As Takeda Narrows Focus
MacroGenics, Merck Seize Gastric Cancer Opportunity With Margetuximab, Keytruda Combo
Janssen, MacroGenics sign potential $575m+ licensing deal
BioNotebook: Two key fires at Retrophin, NewLink; three deals and three financings
Takeda signs option deal for MacroGenics bi-specific antibody
BioNotebook Deals and Data: Zosano/Novo, MacroGenics/Servier, Regulus/Sanofi, Seattle Genetics/Takeda, Sarepta
Gilead targets MacroGenics in potential $1B+ DART deal
Servier buys into MacroGenics' Phase I anticancer MAb
MacroGenics boosted by broad DART antibody deal with Boehringer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel